NanoViricides Inc. (NNVC)
NNVC trades on NYSE in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax), fiscal year ended 2026-06-30, https://www.sec.gov/Archives/edgar/data/1379006/000110465926111390/0001104659-26-111390-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2026-06-30.
Profile
| Field | Value |
|---|---|
| Ticker | NNVC on NYSE |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | Not reported by the screener |
| SEC CIK | 0001379006 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials · 2026
| Line | Value |
|---|---|
| Revenue | $0 |
| Net income | -$8.2M |
| Operating income | -$8.3M |
| Net margin | Needs revenue and net income |
| Operating margin | Operating income not reported |
| Revenue growth | No prior-year revenue to compare |
| Cash | $2.8M |
| Total assets | $9.9M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | Needs market cap and revenue |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | States substantial doubt about continuing as a going concern. "As a result, substantial doubt exists about the Company's ability to continue as a going concern." | 10-K 2026-09-28 |
| Cash and burn | $2.8M cash; operating cash flow -$1.9M a quarter. | Report 2026-06-30 |
| Shares outstanding | 25,525,000 (2026-09-28); 17,431,000 a year earlier; 11,746,000 three years earlier. | Cover page 2026-09-28 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 4 S-3/F-3 shelf filings; 5 424B5 takedowns, 5 at the market | Latest 2026-10-21 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | EisnerAmper LLP, Iselin, New Jersey, United States | PCAOB Form AP 2026-09-30 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q4 2026 2026-06-30 | $0 | -$2.2M | -$2.1M | $2.8M | No debt tags | $0 | 10-K 2026-09-28 |
| Q3 2026 2026-03-31 | $0 | -$2.0M | -$1.9M | $3.2M | No debt tags | $0 | 10-Q 2026-05-15 |
| Q2 2026 2025-12-31 | $0 | -$2.2M | -$2.0M | $5.2M | No debt tags | $0 | 10-Q 2026-02-17 |
| Q1 2026 2025-09-30 | $0 | -$1.8M | -$1.6M | $1.1M | No debt tags | $0 | 10-Q 2025-11-14 |
| Q4 2025 2025-06-30 | $0 | -$2.1M | -$1.7M | $1.6M | No debt tags | $0 | 10-K 2025-09-29 |
| Q3 2025 2025-03-31 | $0 | -$2.2M | -$2.0M | $2.5M | No debt tags | $0 | 10-Q 2025-05-15 |
| Q2 2025 2024-12-31 | $0 | -$2.0M | -$2.2M | $4.0M | No debt tags | $0 | 10-Q 2025-02-14 |
| Q1 2025 2024-09-30 | $0 | -$3.1M | -$2.6M | $3.9M | No debt tags | $0 | 10-Q 2024-11-14 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2026-10-21 |
| Latest annual report | 10-K | 2026-09-28 |
| Latest quarterly / interim | 10-Q | 2026-05-15 |
| Latest current report FORM 8-K | 8-K | 2026-09-29 |
| Latest proxy | DEF 14A | 2026-10-08 |
Source: SEC EDGAR submissions feed, 556 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -6.8% |
| 1 month | -6.8% |
| 3 months | -9.6% |
| Year to date | +8.8% |
| 1 year | -8.9% |
| From 52-week high | -33.9% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| NSRX | Nasus Pharma Ltd. | $2.66 | -7.32% | $31.2M |
| NXTC | NextCure Inc. | $6.68 | +4.38% | $30.6M |
| PMN | ProMIS Neurosciences Inc. Common Shares (ON) | $3.31 | +0.61% | $29.8M |
| RNTX | Rein Therapeutics Inc. | $0.4000 | -27.55% | $34.5M |
| SCYX | SCYNEXIS Inc. | $2.91 | -9.35% | $29.0M |
| BCTX | BriaCell Therapeutics Corp. Common Shares | $3.30 | -2.65% | $28.8M |
| OSTX | OS Therapies Incorporated | $0.6807 | -8.63% | $35.4M |
| TELO | Telomir Pharmaceuticals Inc. | $0.4810 | -1.96% | $35.4M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier